ES514712A0 - Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b). - Google Patents

Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b).

Info

Publication number
ES514712A0
ES514712A0 ES514712A ES514712A ES514712A0 ES 514712 A0 ES514712 A0 ES 514712A0 ES 514712 A ES514712 A ES 514712A ES 514712 A ES514712 A ES 514712A ES 514712 A0 ES514712 A0 ES 514712A0
Authority
ES
Spain
Prior art keywords
yeast
hbsag
synthesis
purified
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES514712A
Other languages
English (en)
Spanish (es)
Other versions
ES8400877A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23113710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES514712(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California filed Critical University of California
Publication of ES8400877A1 publication Critical patent/ES8400877A1/es
Publication of ES514712A0 publication Critical patent/ES514712A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES514712A 1981-08-04 1982-08-03 Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b). Granted ES514712A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28991581A 1981-08-04 1981-08-04

Publications (2)

Publication Number Publication Date
ES8400877A1 ES8400877A1 (es) 1983-11-16
ES514712A0 true ES514712A0 (es) 1983-11-16

Family

ID=23113710

Family Applications (1)

Application Number Title Priority Date Filing Date
ES514712A Granted ES514712A0 (es) 1981-08-04 1982-08-03 Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b).

Country Status (12)

Country Link
EP (1) EP0072318B1 (Sortimente)
JP (1) JPS5877823A (Sortimente)
AT (1) ATE123225T1 (Sortimente)
CA (1) CA1341642C (Sortimente)
DE (2) DE3280186D1 (Sortimente)
DK (2) DK163931C (Sortimente)
ES (1) ES514712A0 (Sortimente)
GR (1) GR76274B (Sortimente)
HK (1) HK64591A (Sortimente)
IE (1) IE65996B1 (Sortimente)
PT (1) PT75374B (Sortimente)
SG (1) SG58191G (Sortimente)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
DE3381619D1 (de) * 1982-08-16 1990-07-05 Chemo Sero Therapeut Res Inst Pendelvektor.
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
US4876197A (en) * 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341116C (en) * 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
JPS6078999A (ja) * 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
JPS60104020A (ja) * 1983-10-14 1985-06-08 メルク　エンド　カムパニー　インコーポレーテツド Ａ型肝炎‐タンパク質サブユニツト抗原
EP0164556B1 (en) * 1984-05-11 1994-03-02 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
ATE73349T1 (de) * 1984-06-18 1992-03-15 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
JP2615027B2 (ja) * 1985-04-08 1997-05-28 アムジェン インコーポレイテッド 外来遺伝子の転写を制御するための方法及びハイブリッドプロモーター
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
EP0233937B1 (en) * 1985-08-15 1993-01-13 Amgen Inc. Fermentation methods for hepatitis vaccine production
JP2810364B2 (ja) * 1985-10-04 1998-10-15 ジ・アップジョン・カンパニー 偽狂犬病ウイルス蛋白質
US4935349A (en) * 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
JPH089637B2 (ja) * 1986-06-18 1996-01-31 財団法人阪大微生物病研究会 Ｂ型肝炎ウイルス抗原とその製造法
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
JPH02501107A (ja) * 1986-11-01 1990-04-19 ブリティッシュ　バイオーテクノロジー　リミテッド 微粒子ハイブリッドｈｉｖ抗原
EP0280470B1 (en) * 1987-02-27 1993-07-07 Merck & Co. Inc. Method of purifying recombinant pres-1/s-2/s hepatitis b antigen from yeast
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
KR890701742A (ko) * 1987-06-22 1989-12-21 메디코 랩스 에이지 이형바이러스 펩티드 입자 임뮤노겐
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
IL90161A0 (en) * 1988-05-13 1989-12-15 Phillips Petroleum Co Expression of hepatitis b s and pres2 proteins in methylotrophic yeasts
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2270892A1 (en) * 1974-05-14 1975-12-12 Inst Francais D Immunologie Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae
DD147855A5 (de) * 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
JPH0314840A (ja) * 1988-12-28 1991-01-23 Kureha Chem Ind Co Ltd 弗化ビニリデン系ポリマー二軸冷延伸フィルムおよびその製造方法

Also Published As

Publication number Publication date
HK64591A (en) 1991-08-23
PT75374A (en) 1982-09-01
JPH0526798B2 (Sortimente) 1993-04-19
DK347682A (da) 1983-02-05
DK163931B (da) 1992-04-21
ES8400877A1 (es) 1983-11-16
DK114791A (da) 1991-06-14
CA1341642C (en) 2023-02-21
EP0072318B1 (en) 1990-05-30
DK169152B1 (da) 1994-08-29
DE3280186D1 (de) 1990-07-05
SG58191G (en) 1993-02-19
EP0072318A3 (en) 1983-03-16
DE3280468D1 (de) 1995-07-06
EP0072318A2 (en) 1983-02-16
IE65996B1 (en) 1995-11-29
DK114791D0 (da) 1991-06-14
PT75374B (en) 1985-12-13
ATE123225T1 (de) 1995-06-15
DE3280468T2 (de) 1995-12-07
GR76274B (Sortimente) 1984-08-04
JPS5877823A (ja) 1983-05-11
DK163931C (da) 1992-09-14

Similar Documents

Publication Publication Date Title
ES514712A0 (es) Procedimiento de preparacion de hb1ag (antigeno superficial de la hepatitis b).
IL95153A0 (en) Novel antigens and their production
EP0291586A3 (en) Recombinant hepatitis b surface antigen and vaccine containing it
KR920007683B1 (ko) HBs항원의 정제방법
PL279426A1 (en) Method of intensifying generation of antigenic hbv particles containing essentially s and pre s2 proteins
CA1216790A (en) Method for purification of hepatitis b virus surface antigen
DE3382704D1 (de) Rekombinante dns-molekuele die hepatitis-b-oberflaechenantigen kodieren, deren herstellung und abgeleitete vakzine.
EP0340806A3 (en) Synthesis of human virus antigens by yeast
AU598181B2 (en) Composition useful for obtaining vaccines containing particles carrying the surface antigene of hepatitis b virus and the receptor of polymerized human serum albumin, animal cells capable of producing such particles and method for the obtention thereof
ATE109353T1 (de) Verfahren zur herstellung eines impfstoffs gegen hepatitis b.
JPS57209298A (en) Recombinant dna, its preparation, and host transformed therewith